Semax/Selank: Research Blend Profile

Semax and Selank are the two most heavily referenced peptides to come out of the Russian regulatory-neuropeptide program, and they are often supplied together because their reported activities sit on different pathways rather than the same one. This profile covers what each constituent is, the research each carries in the literature, and why the pair is co-formulated. For the wider class these belong to, see the neuropeptides overview.

What is the Semax/Selank blend?#

The Semax/Selank blend is a single research vial holding two distinct heptapeptides rather than one molecule. Both share the same design signature: a short peptide modeled on an endogenous parent fragment, then capped with a C-terminal Pro-Gly-Pro extension that slows enzymatic breakdown. Semax is built from a fragment of adrenocorticotropic hormone (ACTH); Selank is built from tuftsin, a naturally occurring immunomodulatory tetrapeptide. Because the two act on unrelated signaling systems, a co-formulation is studied when a protocol wants both present in a fixed ratio, and the sensible identity anchor for the product is the two verifiable sequences below rather than any single molecular weight.

What does each constituent contribute to the research?#

The two peptides are studied for different things, which is the whole reason they appear together. Semax is the neurotrophic constituent: its most-cited reported mechanism is upregulation of brain-derived neurotrophic factor (BDNF) expression and related CNS-signaling activity, and because it lacks the hormonal action of its ACTH parent, the literature treats it as a pure neuropeptide rather than an endocrine agent. Selank is the regulatory constituent: derived from tuftsin, it is studied for GABAergic and broader regulatory signaling, and its tuftsin lineage keeps it in the immunomodulatory-peptide conversation as well. A comparative study in a 6-OHDA rat model (PMID 28702721) examined both peptides side by side, explicitly describing Semax as an ACTH-fragment peptide and Selank as a tuftsin analog. The full head-to-head between the two is covered in Semax vs Selank.

What does the research literature study?#

Most of the literature studies Semax and Selank as individual compounds, and the blend inherits both bodies of work. Both are members of a group the field calls highly stable regulatory oligopeptides (PMID 14682258), a designation that comes from the Pro-Gly-Pro stabilization they share. Beyond their headline pathways, older work has looked at the pair on the same biochemical endpoints: one report examined Semax and Selank inhibition of enkephalin-degrading enzymes in human serum (PMID 11443939), and another compared the anticoagulant activity of proline-containing oligopeptides including both (PMID 16634437). Across all of it the framing is the same: these are preclinical, mechanism-level investigations in cell and animal models, and none of the work establishes effects in people.

Where the blend sits in the neuropeptide class#

Within the neuropeptide class Nexara tracks, Semax and Selank are the engineered-analog end of the spectrum — designed sequences stabilized for the laboratory, in contrast to native signaling peptides like DSIP whose mechanism is still unsettled. The blend is simply the two of them held in one vial, which is why it is studied as a paired research tool rather than a novel entity: each constituent behaves as it does on its own, and the interest is in having both pathways represented at once. Each constituent is also sold and profiled separately — Semax and Selank — for protocols that want only one.

Handling and storage#

The blend is supplied as a co-lyophilized white powder and dissolved prior to use, the same as the single-peptide catalog. Because both constituents are short Pro-Gly-Pro-stabilized heptapeptides, they are handled together without special steps: the reconstitution primer covers solvent selection and gentle mixing to avoid aggregation, while the cold-chain article covers how stability changes once the powder is in solution. Lyophilized material is kept cold and protected from light, and freeze-thaw cycles are minimized once reconstituted.

Sources and further reading#

• Peptides Semax and Selank affect the behavior of rats in a 6-OHDA-induced parkinsonism model (PMID 28702721): a preclinical rat study examining both peptides side by side and describing Semax as an ACTH-fragment analog and Selank as a tuftsin analog.
• Highly stable regulatory oligopeptides: experience and applications (PMID 14682258): a review of Pro-Gly-Pro-stabilized regulatory peptides that situates the design shared by Semax and Selank.
• Semax and Selank inhibit the enkephalin-degrading enzymes from human serum (PMID 11443939): a biochemical study of both heptapeptides on the same enzyme endpoint.
• Comparison of anticoagulant effects of regulatory proline-containing oligopeptides, including Semax and Selank (PMID 16634437): a comparative study placing both peptides within the proline-containing glyproline family.